A Case of Immune Aplastic Anemia during Combined Treatment with Atezolizumab and Chemotherapy for Non-Small Cell Lung Cancer

被引：1

作者：

Matsuki, Satoru ^{[1
]}

Taniuchi, Namiko ^{[1
]}

Okada, Naoko ^{[1
]}

Sato, Junpei ^{[1
]}

Nishijima, Nobuhiko ^{[1
]}

Kamio, Koichiro ^{[1
]}

Motoda, Norio ^{[2
]}

Okamoto, Muneo ^{[3
]}

Seike, Masahiro ^{[4
]}

Azuma, Arata ^{[1
]}

机构：

[1] Nippon Med Sch Musashi Kosugi Hosp, Dept Pulm Med, 1 383 Kosugi Cho,Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan

[2] Nippon Med Sch Musashi Kosugi Hosp, Dept Diagnost Pathol, Kawasaki, Kanagawa, Japan

[3] Nippon Med Sch, Dept Hematol, Tokyo, Japan

[4] Grad Sch Med, Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan

来源：

JOURNAL OF NIPPON MEDICAL SCHOOL | 2024年 / 91卷 / 03期

关键词：

atezolizumab; aplastic anemia; immune checkpoint inhibitor; immune-related adverse event; non-small cell lung cancer; ADVERSE EVENTS;

D O I：

10.1272/jnms.JNMS.2024_91-302

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune check point inhibitors (ICIs) have durable antitumor effects. However, autoimmune toxicities, termed immune-related adverse events, occur in some patients. We report a case of severe immune aplastic anemia (AA) in a patient with non -small cell lung cancer who was receiving atezolizumab with bevacizumab/carboplatin/paclitaxel. Although the cancer has not recurred, his bone marrow is depleted and he did not respond to immunosuppressive therapy. He has survived for 1.5 years with blood transfusions and infection control. Immune AA associated with ICIs is rare, and a treatment has not yet been established. This case report provides information on the management and treatment response of patients with AA caused by ICIs. Further studies should investigate the mechanism and pathogenesis of immune AA caused by ICIs.

引用

页码：339 / 346

页数：8

共 20 条

[1] Hematologic Complications of Immune Checkpoint Inhibitors [J].

Davis, Elizabeth J. ;

Salem, Joe-Elie ;

Young, Arissa ;

Green, Jennifer R. ;

Ferrell, P. Brent ;

Ancell, Kristin K. ;

Lebrun-Vignes, Benedicte ;

Moslehi, Javid J. ;

Johnson, Douglas B. .

ONCOLOGIST, 2019, 24 (05) :584-588

[2]

Delaney N, 2019, LANCET HAEMATOL, V6, pE48, DOI [10.1016/52352-3026(18)30175-3, 10.1016/S2352-3026(18)30175-3]

[3] Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer [J].

Ferrara, Roberto ;

Imbimbo, Martina ;

Malouf, Reem ;

Paget-Bailly, Sophie ;

Calais, Francois ;

Marchal, Corynne ;

Westeel, Virginie .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (04)

[4] Hematological immune related adverse events after treatment with immune checkpoint inhibitors [J].

Kramer, Rafaela ;

Zaremba, Anne ;

Moreira, Alvaro ;

Ugurel, Selma ;

Johnson, Douglas B. ;

Hassel, Jessica C. ;

Salzmann, Martin ;

Gesierich, Anja ;

Weppler, Alison ;

Spain, Lavinia ;

Loquai, Carmen ;

Dudda, Milena ;

Pfoehler, Claudia ;

Hepner, Adriana ;

Long, Georgina, V ;

Menzies, Alexander M. ;

Carlino, Matteo S. ;

Sachse, Michael M. ;

Lebbe, Celeste ;

Baroudjian, Barouyr ;

Enokida, Tomohiro ;

Tahara, Makoto ;

Schlaak, Max ;

Hayani, Kinan ;

Broeckelmann, Paul J. ;

Meier, Friedegund ;

Reinhardt, Lydia ;

Friedlander, Philip ;

Eigentler, Thomas ;

Kaehler, Katharina C. ;

Berking, Carola ;

Zimmer, Lisa ;

Heinzerling, Lucie .

EUROPEAN JOURNAL OF CANCER, 2021, 147 :170-181

[5] Hematologic complications of immune checkpoint inhibitors [J].

Kroll, Michael H. ;

Rojas-Hernandez, Cristhiam ;

Yee, Cassian .

BLOOD, 2022, 139 (25) :3594-3604

[6] Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? [J].

Michot, J. M. ;

Lazarovici, J. ;

Tieu, A. ;

Champiat, S. ;

Voisin, A. L. ;

Ebbo, M. ;

Godeau, B. ;

Michel, M. ;

Ribrag, V. ;

Lambotte, O. .

EUROPEAN JOURNAL OF CANCER, 2019, 122 :72-90

[7] Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review [J].

Omar, Nabil E. ;

El-Fass, Kareem A. ;

Abushouk, Abdelrahman I. ;

Elbaghdady, Noha ;

Barakat, Abd Elmonem M. ;

Noreldin, Ahmed E. ;

Johar, Dina ;

Yassin, Mohamed ;

Hamad, Anas ;

Elazzazy, Shereen ;

Dermime, Said .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[8] Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L [J].

Sakata, Shinya ;

Otsubo, Kohei ;

Yoshida, Hisako ;

Ito, Kentaro ;

Nakamura, Atsushi ;

Teraoka, Shunsuke ;

Matsumoto, Naohisa ;

Shiraishi, Yoshimasa ;

Haratani, Koji ;

Tamiya, Motohiro ;

Ikeda, Satoshi ;

Miura, Satoru ;

Tanizaki, Junko ;

Omori, Shota ;

Yoshioka, Hiroshige ;

Hata, Akito ;

Yamamoto, Nobuyuki ;

Nakagawa, Kazuhiko .

CANCER SCIENCE, 2022, 113 (01) :221-228

[9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update [J].

Schneider, Bryan J. ;

Naidoo, Jarushka ;

Santomasso, Bianca D. ;

Lacchetti, Christina ;

Adkins, Sherry ;

Anadkat, Milan ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Davies, Marianne J. ;

Ernstoff, Marc S. ;

Fecher, Leslie ;

Ghosh, Monalisa ;

Jaiyesimi, Ishmael ;

Mammen, Jennifer S. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Reichner, Cristina A. ;

Seigel, Carole ;

Song, Jung-Min ;

Spira, Alexander ;

Suarez-Almazor, Maria ;

Swami, Umang ;

Thompson, John A. ;

Vikas, Praveen ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Funchain, Pauline ;

Bollin, Kathryn .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (36) :4073-+

[10] Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure [J].

Seiki, Yu ;

Sasaki, Yumi ;

Hosokawa, Kohei ;

Saito, Chizuru ;

Sugimori, Naomi ;

Yamazaki, Hirohito ;

Takami, Akiyoshi ;

Nakao, Shinji .

HAEMATOLOGICA, 2013, 98 (06) :901-907

← 1 2 →